Fortis Malar Hospitals Ltd (523696)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Fortis Malar's revenue was ₹0.0 Cr (-95.5% year on year), and net profit ₹0.2 Cr (-96.3% year on year); the operating margin was -37333.3%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | -95.5% | — |
| Operating profit | ₹-0.3 | loss widened | loss narrowed |
| Net profit | ₹0.2 | -96.3% | from loss |
| EPS (₹) | 0.08 | -96.4% | from loss |
| Operating margin | -37333.3% | — | — |
📢 Recent Corporate Announcements
Fortis Malar Hospitals reported zero operational revenue for the quarter ended June 30, 2026, as it remains a non-operating entity following its 2024 business divestment. The company recorded a marginal consolidated net profit of Rs 0.09 crore, a significant decline from Rs 4.15 crore in Q1 FY26, which was inflated by a one-time provision reversal of Rs 4.08 crore. With a cash and bank balance of Rs 34.59 crore (representing ~36% of its market cap), the management maintains a 'going concern' status while evaluating restructuring options. The company is currently managing legacy liabilities, including contested medico-legal and tax claims totaling approximately Rs 11.25 crore.
- Operational revenue remained at Rs 0.00 crore for the quarter ended June 30, 2026.
- Cash and bank balances stood at Rs 34.59 crore, providing a liquidity buffer against a market cap of Rs 95 crore.
- Consolidated Net Profit fell to Rs 0.09 crore from Rs 4.15 crore in the year-ago quarter.
- Contested medico-legal claims are estimated at ~Rs 6.49 crore, with additional tax demands (VAT, GST, Income Tax) totaling ~Rs 4.76 crore.
- The Board is currently progressing with the finalization of a corporate restructuring plan in consultation with legal advisors.
Fortis Malar Hospitals remains a non-operational entity following its 2024 business divestment, reporting zero revenue for the quarter ended June 30, 2026. The company reported a marginal net profit of approximately ₹0.17 Cr (EPS ₹0.09), primarily sustained by its cash and bank balances of ₹34.59 Cr. This cash reserve is significant, representing roughly 36% of its ₹95 Cr market capitalization. Management continues to evaluate restructuring options with no immediate visibility on new business operations.
- Reported zero operational revenue for Q1 FY27, consistent with its non-operational status since February 2024.
- Maintains cash and bank balances of ₹34.59 Cr, which management deems sufficient to meet foreseeable obligations.
- Total contested contingent liabilities identified at approximately ₹11.25 Cr, including ₹6.49 Cr in medico-legal claims.
- Reported a consolidated EPS of ₹0.09 for the quarter, resulting in a nominal net profit of ~₹0.17 Cr.
- Management and Board are currently finalizing a corporate restructuring plan in consultation with legal and financial advisors.
Fortis Malar Hospitals held its 35th Annual General Meeting on July 29, 2026, to approve the FY26 financial statements and the re-appointment of Mr. Daljit Singh as Director. The company remains in a non-operational state following the divestment of its hospital business in February 2024, reporting zero revenue for the full year FY26. While the meeting was procedural, the company continues to evaluate restructuring options to address its lack of an active business model. The current market cap of Rs 93 Cr is supported by a net worth of Rs 34 Cr and zero debt.
- 35th Annual General Meeting conducted on July 29, 2026, with 81 members in attendance.
- Adoption of Audited Financial Statements for FY26 where the company reported Rs 0 revenue.
- Re-appointment of Mr. Daljit Singh as a Director who retired by rotation.
- Voting results for all resolutions to be declared on or before July 31, 2026.
- Statutory and Secretarial Auditor reports contained no qualifications or adverse remarks.
Fortis Malar Hospitals has scheduled a board meeting for August 4, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company is currently in a non-operational state following the divestment of its healthcare business in February 2024, reporting zero revenue in the most recent quarters. The trading window for company securities is closed until August 6, 2026. With a market cap of Rs 94 Cr and zero debt, the company remains in a restructuring phase with no active business operations.
- Board meeting scheduled for August 4, 2026, to consider Q1 FY27 results
- Trading window remains closed until August 6, 2026, per SEBI regulations
- Company reported Rs 0.0 Cr revenue for the quarter ended March 2026
- Promoter holding remains steady at 62.71% as of June 2026
- Current market capitalization stands at Rs 94 Cr with a net worth of Rs 34 Cr
Financial Performance
Revenue Growth by Segment
Revenue from operations has effectively dropped to zero following the 100% divestment of business operations to MGM Healthcare Private Limited on February 1, 2024. The company currently has no operating segments.
Geographic Revenue Split
Not applicable as the company has ceased all business operations post-divestment; previously, 100% of revenue was derived from India.
Profitability Margins
Operating margins are not applicable due to lack of business activity. However, the company declared significant dividends totaling INR 42.5 per share in FY25, consisting of INR 40 per share (April 12, 2024) and INR 2.5 per share (May 17, 2024).
EBITDA Margin
Not disclosed for the current period as the company has no active operations; cash flows are currently utilized for settling legacy obligations and legal contingencies.
Capital Expenditure
There is no planned capital expenditure as the company is currently evaluating corporate restructuring options and has no visibility of commencing new business operations.
Credit Rating & Borrowing
Not disclosed in available documents; however, the company maintains sufficient cash and bank balances to meet all foreseeable financial obligations and legal settlements.
Operational Drivers
Raw Materials
Not applicable; the company has no manufacturing or service operations following the slump sale of its hospital business.
Capacity Expansion
Current capacity is zero units/beds as the entire business was transferred to MGM Healthcare. There are no plans for expansion.
Logistics & Distribution
0% of revenue.
Strategic Growth
Expected Growth Rate
0%
Growth Strategy
The company is currently in a non-operational state. Growth is dependent on the finalization of a corporate restructuring plan being evaluated by the Board in consultation with legal advisors and merchant bankers. There is currently no visibility on new business commencement.
Products & Services
None; the company previously provided healthcare and hospital services which were divested in February 2024.
Brand Portfolio
Fortis Malar (Note: The business associated with this brand was sold to MGM Healthcare).
New Products/Services
0%; no new products or services are currently planned or launched.
Market Expansion
None; the company has exited its primary market of healthcare services in Chennai.
Market Share & Ranking
0%; the company has exited the healthcare provider market.
Strategic Alliances
Divestment agreement with MGM Healthcare Private Limited completed on February 1, 2024.
External Factors
Industry Trends
The Indian healthcare sector is growing via digital health (ABDM) and AI, but Fortis Malar is not positioned to capture this growth as it has divested its operational assets.
Competitive Landscape
The company has no direct competitors in its current state as a non-operating shell entity evaluating restructuring.
Competitive Moat
The company currently has no competitive moat as it lacks active operations, employees, and infrastructure.
Macro Economic Sensitivity
Low sensitivity to GDP/Inflation currently as the company is not operating; however, legal and tax settlement costs may be impacted by regulatory shifts.
Geopolitical Risks
Low, as operations are domestic and currently inactive.
Regulatory & Governance
Industry Regulations
The company must comply with the Companies Act 2013 and SEBI LODR regulations during its restructuring phase; legacy healthcare regulations no longer apply to its daily operations.
Taxation Policy Impact
The company is currently contesting VAT, GST, and Income Tax appeals; changes in fiscal policy could impact the settlement values of these legacy liabilities.
Legal Contingencies
The company is managing multiple pending legal matters including medico-legal cases, VAT appeals, GST appeals, and Income tax appeals. Management assesses the financial risk as remote but maintains cash reserves for these contingencies.
Risk Analysis
Key Uncertainties
The primary risk is the 100% uncertainty regarding the commencement of any new business operations and the outcome of the ongoing corporate restructuring evaluation.
Geographic Concentration Risk
100% of legacy assets and legal liabilities are concentrated in India.
Third Party Dependencies
High dependency on legal and financial advisors to determine the future course of the company.
Technology Obsolescence Risk
High risk; as the company remains inactive, it falls behind in the rapid technological transformation (AI, robotics) occurring in the healthcare sector.
Credit & Counterparty Risk
Receivables quality is not a major factor as operations have ceased; focus is on the settlement of existing creditors and legal claimants.
